ESMO 2024: Targeting the Treatment Challenges of Small Cell Lung Cancer - Episode 11

Insights from ARTEMIS-001

November 4, 2024

Melissa L. Johnson, MD, Wade T. Iams, MD, Ticiana A. Leal, MD, Triparna Sen, PhD

Panelists discuss how preliminary results from the pPhase 3 ARTEMIS-001 study indicate that iIfinatamab dDeruxtecan, a B7-H3 antibody-drug conjugate, demonstrates promising antitumor activity in relapsed small cell lung cancer, with a notable partial response rate and manageable safety profile among treated patients.

EP. 1: Current Landscape of First-Line Treatment for Limited-Stage SCLC: Diagnostic Workup & Multidisciplinary Approaches

EP. 2: Surgical and Radiotherapy Choices in Limited-Stage SCLC

EP. 3: Durvalumab in LS-SCLC: Exploring Phase 3 ADRIATIC Trial Outcomes and Implications

EP. 4: Immunotherapy in Limited-Stage SCLC

EP. 5: Defining Platinum Sensitivity in SCLC

EP. 6: Changing Standard of Care: Potential of Tarlatamab in SCLC Treatment

EP. 7: Adverse Event Management: CRS and ICANS with Tarlatamab

EP. 8: Tarlatamab in Combination Therapy: Future Potential for SCLC

EP. 9: Ifinatamab Deruxtecan and B7-H3 in SCLC

EP. 10: Comparing Treatment Schedules: Ifinatamab Deruxtecan vs Amrubicin, Topotecan, and Lurbinectedin in SCLC

Now Viewing

EP. 11: Insights from ARTEMIS-001

EP. 12: Targeted Therapies and Biomarkers for SCLC: What’s Next on the Horizon

Video content above is prompted by the following:

Dr Iams: Please provide your insights on outcomes from the ongoing Phase I ARTEMIS-001[study into which 11 of 53 (20.75%) patients with small cell lung cancer were enrolled.